Relevant bibliographies by topics / Cancer chemotherapies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cancer chemotherapies'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer chemotherapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer chemotherapies"

1

Villasana, M., and G. Ochoa. "Heuristic Design of Cancer Chemotherapies." IEEE Transactions on Evolutionary Computation 8, no. 6 (2004): 513–21. http://dx.doi.org/10.1109/tevc.2004.834154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ranftler, Matthias, and Kathrin Strasser-Weippl. "New chemotherapies in breast cancer." memo - Magazine of European Medical Oncology 10, no. 3 (2017): 127–31. http://dx.doi.org/10.1007/s12254-017-0348-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Froelich, Warren. "Cardiotoxic Chemotherapies in Young Cancer Survivors." Oncology Times 43, no. 11 (2021): 48. http://dx.doi.org/10.1097/01.cot.0000754744.48767.ee.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chaffer, Christine Louise, Heloisa H. Milioli, Beatriz P. San Juan, Rachel F. Dear, and Jia (Jenny) Liu. "Abstract 4744: State-gating cancer to prevent chemotherapy-resistance." Cancer Research 85, no. 8_Supplement_1 (2025): 4744. https://doi.org/10.1158/1538-7445.am2025-4744.

Full text
Abstract:
Abstract New approaches are urgently required to treat advanced-stage cancers that are therapy resistant and incurable. Furthermore, salvage treatment protocols rely on cytotoxic chemotherapies that actively induce cancer cells to transition into therapy-resistant states via non-genetic mechanisms. We show in large clinical cohorts of triple-negative breast cancer (TNBC) that chemotherapy-induced cell state changes are mediated by androgen receptor (AR) signaling and are associated with poor patient outcome. AR inhibition blocks canonical and non-canonical AR signaling to lock cancer cells in
APA, Harvard, Vancouver, ISO, and other styles
5

Gomes, Ana. "AGE-INDUCED SYSTEMIC REPROGRAMMING DRIVES DRUG RESISTANCE IN LUNG CANCER." Innovation in Aging 7, Supplement_1 (2023): 139–40. http://dx.doi.org/10.1093/geroni/igad104.0457.

Full text
Abstract:
Abstract Lung cancer accounts for the largest number of cancer-associated deaths in the United States. While great strides have been made due to the introduction of immunotherapies and targeted therapies against oncogenic drivers, chemotherapies remain the standard of care for the majority of lung cancer patients. However, many patients do not respond to these treatments or relapse following an initial response. We postulate that part of the problem is the lack of consideration in preclinical research and clinical trials of the main driver of lung tumorigenesis, the aging process. Here, we sho
APA, Harvard, Vancouver, ISO, and other styles
6

He, Ji, Erika Fortunati, Dong-Xu Liu, and Yan Li. "Pleiotropic Roles of ABC Transporters in Breast Cancer." International Journal of Molecular Sciences 22, no. 6 (2021): 3199. http://dx.doi.org/10.3390/ijms22063199.

Full text
Abstract:
Chemotherapeutics are the mainstay treatment for metastatic breast cancers. However, the chemotherapeutic failure caused by multidrug resistance (MDR) remains a pivotal obstacle to effective chemotherapies of breast cancer. Although in vitro evidence suggests that the overexpression of ATP-Binding Cassette (ABC) transporters confers resistance to cytotoxic and molecularly targeted chemotherapies by reducing the intracellular accumulation of active moieties, the clinical trials that target ABCB1 to reverse drug resistance have been disappointing. Nevertheless, studies indicate that ABC transpor
APA, Harvard, Vancouver, ISO, and other styles
7

Fakiruddin, Kamal Shaik, Moon Nian Lim, Norshariza Nordin, Rozita Rosli, and Syahril Abdullah. "Chemo-Sensitization of CD133+ Cancer Stem Cell Enhances the Effect of Mesenchymal Stem Cell Expressing TRAIL in Non-Small Cell Lung Cancer Cell Lines." Biology 10, no. 11 (2021): 1103. http://dx.doi.org/10.3390/biology10111103.

Full text
Abstract:
Pre-clinical studies have demonstrated the efficacy of mesenchymal stem cells (MSCs) expressing tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or MSC-TRAIL against several tumors. However, due to the existence of cancer stem cells (CSCs), some tumors, including non-small cell lung cancer (NSCLC), exhibit TRAIL resistance. This study was designed to evaluate the capacity of using first-line chemotherapies including cisplatin, 5-fluorouracil (5-FU) and vinorelbine to act as a chemo-sensitizer on CD133+ (prominin-1 positive) CSCs derived from NSCLC cell lines (A549, H460 an
APA, Harvard, Vancouver, ISO, and other styles
8

Si, Yingnan, Ya Zhang, Hanh Giai Ngo, et al. "Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer." Cancers 13, no. 15 (2021): 3749. http://dx.doi.org/10.3390/cancers13153749.

Full text
Abstract:
Triple-negative breast cancers (TNBCs) are highly aggressive and recurrent. Standard cytotoxic chemotherapies are currently the main treatment options, but their clinical efficacies are limited and patients usually suffer from severe side effects. The goal of this study was to develop and evaluate targeted liposomes-delivered combined chemotherapies to treat TNBCs. Specifically, the IC50 values of the microtubule polymerization inhibitor mertansine (DM1), mitotic spindle assembly defecting taxane (paclitaxel, PTX), DNA synthesis inhibitor gemcitabine (GC), and DNA damage inducer doxorubicin (A
APA, Harvard, Vancouver, ISO, and other styles
9

Ranieri, Girolamo, and Carmelo Laface. "Loco-Regional and Systemic Chemotherapies for Hepato-Pancreatic Tumors: Integrated Treatments." Cancers 12, no. 10 (2020): 2737. http://dx.doi.org/10.3390/cancers12102737.

Full text
Abstract:
This Special Issue of Cancers, titled “Loco-Regional Arterial Chemotherapies Alone or in Combination with Systemic Treatments for Primary and Secondary Hepato-Pancreatic Tumors”, focuses on new possible strategies to treat only liver disease (or mainly liver disease) through the combination of loco-regional and systemic chemotherapies [...]
APA, Harvard, Vancouver, ISO, and other styles
10

Herzog, Thomas J., Thomas C. Krivak, John Paul Diaz, et al. "Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial." Journal of Clinical Oncology 42, no. 16_suppl (2024): 5518. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5518.

Full text
Abstract:
5518 Background: Patients with recurrent platinum-resistant epithelial ovarian cancer (EOC) have poor clinical outcomes, owing in large part to the presence of therapy-resistant cancer stem cells (CSCs). A randomized clinical trial (NCT03949283) was conducted to determine if chemotherapy regimens guided by the CSCs functional assay (ChemoID) can improve objective response rate (ORR) in patients with recurrent platinum-resistant EOC when compared to empiric treatment selection. Methods: Patients with recurrent platinum-resistant EOC who had failed standard of care (SOC) therapy, were randomly a
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer chemotherapies"

1

Gharaibeh, Mahdi, and Mahdi Gharaibeh. "Optimizing Economic Evaluation of First-Line Chemotherapies for Metastatic Pancreatic Cancer for the UK and the US." Diss., The University of Arizona, 2016. http://hdl.handle.net/10150/621294.

Full text
Abstract:
Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United Kingdom (UK) and the United States (US). Most of the cases are diagnosed in the metastatic stage (MPC) and the disease is associated with a significant economic and quality of life burden. Chemotherapy with gemcitabine (GEM) is the standard of care. Combination regimens such as cisplatin plus GEM (CIS+GEM), capecitabine plus GEM (CAP+GEM), nab-paclitaxel plus gemcitabine (NAB-P+GEM), FOLFIRINOX (FFX), and oxaliplatin plus GEM (OX+GEM) showed an improvement in the survival outcome when compared to GEM alone.
APA, Harvard, Vancouver, ISO, and other styles
2

AQBI, HUSSEIN F. "Preconditioning of the tumor microenvironment by means of low dose chemotherapies for an effective immunotherapy of breast cancer." VCU Scholars Compass, 2019. https://scholarscompass.vcu.edu/etd/6025.

Full text
Abstract:
Breast cancer mortality is mainly due to distant recurrence of the disease arising from dormant tumor cells established by cancer therapies. Patients who initially respond to cancer therapies often succumb to distant recurrence of the disease. It is not clear why people with the same type of breast cancer respond to treatments differently; some escape from dormancy and relapse earlier than others. In addition, some tumor clones respond to immunotherapy while others do not. We investigated how autophagy plays a role in accelerating or delaying recurrence of neu overexpressing mouse mammary carc
APA, Harvard, Vancouver, ISO, and other styles
3

Adjemian, Sandy. "Facteurs essentiels pour le succès des chimiothérapies immunogènes." Thesis, Paris 11, 2012. http://www.theses.fr/2012PA11T090/document.

Full text
Abstract:
La plupart des chimiothérapies sont connues pour exercer une immunosuppression en plus de leur effet cytotoxique, car elles ciblent sans distinction les cellules à prolifération rapide telles que les cellules tumorales ainsi que les cellules du système immunitaire. Cependant, la radiothérapie ainsi que certaines chimiothérapies comme les anthracyclines ou l’oxaliplatine ont montré une propriété immunostimulante, grâce à l’induction d’une mort cellulaire dite immunogène. Cette mort cellulaire se caractérise par la libération de signaux de danger par la cellule mourante qui vont activer le systè
APA, Harvard, Vancouver, ISO, and other styles
4

Cherradi, Sara. "Les claudines dans le cancer colorectal : ciblage thérapeutique de la claudine-1." Thesis, Montpellier, 2018. http://www.theses.fr/2018MONTT082.

Full text
Abstract:
En France, le cancer colorectal (CCR) est la 2ème cause de décès par cancer. Chez les patients, lorsque la tumeur est localisée, elle est réséquée par chirurgie. Toutefois, 50% des patients sont diagnostiqués à un stade métastatique, ces patients sont alors traités par chimiothérapie (FOLFOX/FOLFIRI), souvent en combinaison avec des thérapies ciblées incluant des anticorps tel que le Cetuximab (anti-EGFR) ou le Bevacizumab (anti-VEGF). Cependant, il reste encore environ 40% des patients qui ne répondent pas au traitement et l’une des causes les mieux établies est l'influence des mutations de l
APA, Harvard, Vancouver, ISO, and other styles
5

Meunier, Mélina. "Étude de biomarqueurs prédisant l’efficacité et la réponse anti-tumorale d’une thérapie séquentielle "chimiothérapies puis Glyceryl Trinitrate" pour le traitement du cancer colorectal." Electronic Thesis or Diss., Bourgogne Franche-Comté, 2024. http://www.theses.fr/2024UBFCI017.

Full text
Abstract:
Le traitement des cancers colorectaux à des stades avancés repose sur l’exérèse chirurgicale, précédée et/ou suivie d’un traitement par chimio et/ou radiothérapie. Toutefois, la résistance des cellules cancéreuses limite l’efficacité de ces traitements. Pour améliorer leur activité anti-tumorale nous avons développé une nouvelle combinaison anti-cancéreuse associant les chimiothérapies standards à un médicament donneur de monoxyde d’azote (NO) appelé le Glyceryl Trinitrate (GTN).Au sein du microenvironnement tumoral, certaines cytokines naturellement présentes et/ou chimioinduites comme le TNF
APA, Harvard, Vancouver, ISO, and other styles
6

Adjemian, Sandy. "Facteurs essentiels pour le succès des chimiothérapies immunogènes." Electronic Thesis or Diss., Paris 11, 2012. http://www.theses.fr/2012PA11T090.

Full text
Abstract:
La plupart des chimiothérapies sont connues pour exercer une immunosuppression en plus de leur effet cytotoxique, car elles ciblent sans distinction les cellules à prolifération rapide telles que les cellules tumorales ainsi que les cellules du système immunitaire. Cependant, la radiothérapie ainsi que certaines chimiothérapies comme les anthracyclines ou l’oxaliplatine ont montré une propriété immunostimulante, grâce à l’induction d’une mort cellulaire dite immunogène. Cette mort cellulaire se caractérise par la libération de signaux de danger par la cellule mourante qui vont activer le systè
APA, Harvard, Vancouver, ISO, and other styles
7

Mercatali, Laura <1977&gt. "Evaluation of Antitumoral activity of bone targeted drugs/conventional chemotherapies and identification of biomarkers for the selection of patients with breast cancer for the bone targeted therapy in adjuvant setting." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2014. http://amsdottorato.unibo.it/6394/1/Mercatali_Laura_tesi.pdf.

Full text
Abstract:
Bone metastases are responsible for different clinical complications defined as skeletal-related events (SREs) such as pathologic fractures, spinal cord compression, hypercalcaemia, bone marrow infiltration and severe bone pain requiring palliative radiotherapy. The general aim of these three years research period was to improve the management of patients with bone metastases through two different approaches of translational research. Firstly in vitro preclinical tests were conducted on breast cancer cells and on indirect co-colture of cancer cells and osteoclasts to evaluate bone targeted the
APA, Harvard, Vancouver, ISO, and other styles
8

Mercatali, Laura <1977&gt. "Evaluation of Antitumoral activity of bone targeted drugs/conventional chemotherapies and identification of biomarkers for the selection of patients with breast cancer for the bone targeted therapy in adjuvant setting." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2014. http://amsdottorato.unibo.it/6394/.

Full text
Abstract:
Bone metastases are responsible for different clinical complications defined as skeletal-related events (SREs) such as pathologic fractures, spinal cord compression, hypercalcaemia, bone marrow infiltration and severe bone pain requiring palliative radiotherapy. The general aim of these three years research period was to improve the management of patients with bone metastases through two different approaches of translational research. Firstly in vitro preclinical tests were conducted on breast cancer cells and on indirect co-colture of cancer cells and osteoclasts to evaluate bone targeted the
APA, Harvard, Vancouver, ISO, and other styles
9

Shreim, Amani. "Cibler le splicéosome : une nouvelle stratégie thérapeutique pour contrecarrer la résistance thérapeutique dans les cancers du poumon ?" Electronic Thesis or Diss., Université Grenoble Alpes, 2024. http://www.theses.fr/2024GRALV023.

Full text
Abstract:
Le cancer du poumon est un problème de santé publique majeur et la première cause de décès par cancer dans le monde. Chez les patients porteurs de carcinomes pulmonaires non à petites cellules (CBnPC), la chimiothérapie à base de sels de platine demeure l’une des pierres angulaires du traitement. Même chez les 30% de patients répondeurs, une résistance survient en quelques mois, rendant impérative la recherche d'alternatives thérapeutiques. L’épissage des ARNs participe au contrôle de l’expression des gènes et à la diversité protéique et met en jeu une machinerie multi-protéique, connue sous l
APA, Harvard, Vancouver, ISO, and other styles
10

Lignet, Floriane. "Approches mathématiques multi-niveaux pour l'étude de la croissance des tumeurs : Application à la morphogenèse du cancer du sein et ciblage thérapeutique de l'angiogenèse du cancer du côlon." Phd thesis, Ecole normale supérieure de lyon - ENS LYON, 2012. http://tel.archives-ouvertes.fr/tel-00844807.

Full text
Abstract:
Les cancers sont l'une des causes majeures de mortalité dans le monde. Les mécanismes en jeu dans la croissance tumorale sont qualitativement connus, mais on se sait pas à l'heure actuelle prédire précisément quel sera le développement d'une tumeur donnée, ni estimer de façon certaine le protocole thérapeutique optimal pour chaque patient. Il est entendu que la modélisation mathématique pourrait apporter des éléments de réponse à ces questions. Durant cette thèse on s'est alors intéressé à la construction de formalismes mathématiques pour décrire la croissance tumorale et l'action de traitemen
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cancer chemotherapies"

1

Pharmaceuticals, Zeneca, ed. What are the critical issues when investigating new chemotherapies for colorectal cancer?: Proceedings of a Zeneca-sponsored satellite symposia held at the ECCO 9 Conference, Hamburg, 17 September 1997. Churchill Livingstone, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

L, Denis, ed. The Medical management of prostate cancer. Springer-Verlag, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hess, Lisa M., David S. Alberts, and Mary C. Clouser. Intraperitoneal therapy for ovarian cancer. Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

P, Workman, Graham M. A, and Imperial Cancer Research Fund (Great Britain)., eds. Pharmacokinetics and cancer chemotherapy. Cold Spring Harbor Laboratory Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1949-, Longo Dan L., ed. Cancer chemotherapy and biotherapy: Principles and practice. 2nd ed. Lippincott-Raven Publishers, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Timothy, Bricker J., Green Daniel M, and D'Angio Giulio J. 1922-, eds. Cardiac toxicity after treatment for childhood cancer. Wiley-Liss, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

International Forum on the Scientific Bases of Cancer Chemoprevention (1996 Bologna, Italy). The scientific bases of cancer chemoprevention: Proceedings of the International Forum on the Scientific Bases of Cancer Chemoprevention, 31 March-2 April 1996. Edited by Davis Walter, Maltoni Cesare, and Soffritti Morando. Elsevier, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

International, Forum on the Scientific Bases of Cancer Chemoprevention (1996 Bologna Italy). The scientific bases of cancer chemoprevention: Proceedings of the International Forum on the Scientific Bases of Cancer Chemoprevention, 31 March-2 April, 1996, Bologna, Italy. Elsevier, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

T, Hill Bridget, and Bellamy Angela S, eds. Antitumor drug-radiation interactions. CRC Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

E, Voest Emile, and D'Amore Patricia A, eds. Tumor angiogenesis and microcirculation. Dekker, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer chemotherapies"

1

Boutayeb, Saber, and Mohammed Anass Majbar. "General Oncology Care in Morocco." In Cancer in the Arab World. Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7945-2_11.

Full text
Abstract:
AbstractThe current population of Morocco is estimated to be 37 million based on the projection of the United Nations data. The median age in the Moroccan population is young. Around 25% of the population is aged under 14 years. Morocco is currently in an epidemiological transition called “double burden,” with the coexistence of infectious and chronic diseases. The most frequent cancers in men are lung, prostate, bladder, colorectum, and lymphoma. Whereas, for women, the most frequent are breast, cervix, colorectum, thyroid, and ovary. The first Moroccan cancer plan (2010–2019) has given the p
APA, Harvard, Vancouver, ISO, and other styles
2

Chang, T. C., H. C. Chang, C. H. Lai, et al. "Adjuvant chemotherapies for small cell carcinoma of the uterine cervix." In Cancer Treatment An Update. Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_100.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Acarbey, Aydin, and Mahmut Gumus. "Rational Sequential Treatment Options for Metastatic Prostate Cancer." In Current Management of Metastatic Prostate Cancer. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359142.14.

Full text
Abstract:
The treatment of metastatic prostate cancer contains various options. Hormonal agents, chemotherapies, targeted therapies and bone modifying agents are used in different combination and sequence nowadays. In this chapter, the importance of sequencing these treatments is depicted. Because of the numerous factors affecting the clinician’s decision making process, there is a need to simplify the treatment algorithms. Our aim is to spotlight on current treatments thanks to the evidence based data. Since there is rapid progress in randomized clinical trials and increasing body of evidence, one shou
APA, Harvard, Vancouver, ISO, and other styles
4

Delitala, Marcello, and Tommaso Lorenzi. "Mathematical Modeling of Cancer Cells Evolution Under Targeted Chemotherapies." In Managing Complexity, Reducing Perplexity. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-03759-2_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hashmi, Shahrukh. "Hematological Malignancies in the UAE." In Cancer Care in the United Arab Emirates. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-6794-0_38.

Full text
Abstract:
AbstractHematologic malignancies make up a substantial portion of overall cancers, and unfortunately, the incidence of hematologic malignancies continues to grow in developed countries. These encompass both inherited and acquired cancers, though complicating the differentiation is the fact that some of the primary immunodeficiencies and bone marrow failure syndromes can lead to the development of leukemia and myelodysplastic syndrome as well, besides lymphomas. Plasma cell dyscrasias are also a complicated group of conditions that include, at one spectrum, AL amyloidosis, which can be rapidly
APA, Harvard, Vancouver, ISO, and other styles
6

Hillejan, L., Chr Pöttgen, M. R. Müller, W. Eberhardt, G. Stüben, and G. Stamatis. "Neoadjuvante Chemotherapie und Chemoradiotherapie beim operiertem nicht-kleinzelligen Bronchialkarzinom Stadium III / Results after Neoadjuvant Chemoradiotherapy of Lung Cancer." In Deutsche Gesellschaft für Chirurgie. Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56458-1_214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Li, Jie Jack. "Imatinib Mesylate (Gleevec)." In Top Drugs. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780199362585.003.0010.

Full text
Abstract:
Great strides had been made in the war against cancer with chemotherapy even before the emergence of protein kinase inhibitors. For instance, prior to vinblastine (1, Velban) became available in 1964 for the treatment of lymphoma, the diagnosis of Hodgkin’s disease (a cancer of the lymph nodes) was virtually a death sentence. Today there is a 90% chance of survival with the treatment by vinca alkaloids such as 1 and other chemotherapies. Similarly, when Sidney Farber discovered the effects of methotrexate (2, Trexall) on leukemia, it marked the beginning of the triumph over childhood leukemia.
APA, Harvard, Vancouver, ISO, and other styles
8

Henry, James R., and Mary M. Mader. "Recent Advances in Antimetabolite Cancer Chemotherapies." In Annual Reports in Medicinal Chemistry. Elsevier, 2004. http://dx.doi.org/10.1016/s0065-7743(04)39013-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sbanotto, Alberto. "Oral complications of cancer." In Gastrointestinal symptoms in advanced cancer patients. Oxford University PressNew York, NY, 2002. http://dx.doi.org/10.1093/oso/9780192632845.003.0005.

Full text
Abstract:
Abstract Oral cavity problems represent a major issue in advanced cancer patients. They may strongly interfere with fundamental functions, namely speaking, eating, and respiration. Moreover, they carry relevant psychosocial consequences. The treatment of these complications should often begin during the initial phases of the illness, when aggressive treatment (e.g. combined chemotherapies and radiotherapies) may produce unavoidable toxicities to normal cells. In this chapter we discuss the most frequent complications of the oral cavity, considering also cancer treatment-related problems, which
APA, Harvard, Vancouver, ISO, and other styles
10

Waldmann, Herman. "Cancer immunology." In Oxford Textbook of Cancer Biology, edited by Francesco Pezzella, Mahvash Tavassoli, and David J. Kerr. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198779452.003.0023.

Full text
Abstract:
Until recently, the prospects for harnessing immune mechanisms to fight cancer were not encouraging. The advent of monoclonal antibodies, both as diagnostics and as probes for molecular function, have been important, while the identification of dendritic cells as a major intermediary between the antigen source and T-cell activation has been crucial. Major advances in molecular biology and the creation of mutant mice lacking defined gene products have pinpointed key molecules influencing immune function. Finally, many translational efforts in vaccination, autoimmune disease, and transplantation
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer chemotherapies"

1

Marshall, Lauren, Isabel Löwstedt, Paul Gatenholm, and Joel Berry. "Prevascularized, Co-Culture Model for Breast Cancer Drug Development." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80409.

Full text
Abstract:
The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of w
APA, Harvard, Vancouver, ISO, and other styles
2

Quinn, A., C. Wong, J. Younus, G. Dranitsaris, R. Goel, and M. Trudeau. "Canadian pattern of care for anemia: comparison of chemotherapies in adjuvant breast cancer setting." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-2118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fan, Jia, Qing H. Meng, Christopher Bone, Stephen Igo, and Ye Hu. "Abstract 598: Circulating peptides for predicting subsequent cardiotoxicity in cancer patients with chemotherapies." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-598.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Leuschner, Carola, Shashi Gavini, and Hector W. Alila. "Abstract 978: Synergistic activity of EP-100 and chemotherapies in cancer cell lines." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-978.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ditto, Andrew J., Nikki K. Robbishaw, Matthew J. Panzner, Wiley J. Youngs, and Yang H. Yun. "Targeting Ovarian Cancer Cells With Rapidly Biodegradable L-Tyrosine Polyphosphate Nanoparticles Decorated With Folate." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53138.

Full text
Abstract:
Chemotherapy employs toxic chemicals to kill rapidly dividing cells. Examples of FDA approved antineoplastic drugs include cisplatin, doxorubicin, and paclitaxel. Since most of these drugs are nonspecific, they also damage normal tissues as well as the aberrant tumors. As a result, non-specific therapies have multiple side effects, which include myelosuppression, mucositis, alopecia, nephrotoxicity, and genotoxcity. In order to minimize these issues, researchers have begun to conjugate antineoplastic chemicals with targeting moieties or encapsulate drugs into nanoparticles decorated with compo
APA, Harvard, Vancouver, ISO, and other styles
6

Zhou, J., J. Hu, Y. Song, and C. Bai. "Clinical Outcomes of Patients with HER2-Mutant Advanced Lung Cancer: Chemotherapies Versus HER2-Directed Therapies." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2455.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sowder, ME, KA Ludwik, L. Pasic, et al. "Abstract P1-06-05: Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p1-06-05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Barch, HP, R. Krutilina, DL Brooks, D. Parke, and TN Seagroves. "Abstract P2-02-01: Inhibition of creatine kinase metabolism represses invasion and sensitizes estrogen-receptor negative breast cancer cells to standard chemotherapies." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p2-02-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tury, Sandrine, Sophie Vacher, Véronique Becette, et al. "Abstract 2031: Antitumoral synergy of iron chelators and chemotherapies in triple-negative breast cancer cell lines and patient-derived xenograft." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-2031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tortorelli, Corinne, Celine Gongora, Doriane Mathe, et al. "1179 Efficacy study of STC-1010 antitumor vaccine associated with standard chemotherapies on MC 38 syngeneic colon cancer tumor model." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.1179.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer chemotherapies"

1

Yang, Rui, You-yang Shi, Xiang-hui Han, and Sheng Liu. The impact of platinum-containing chemotherapies in advanced triple-negative breast cancer: meta-analytical approach to evaluating its efficacy and safety. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.1.0070.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer chemotherapies' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography